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composite "unqualified success" measure, expressing the proportion of patients who achieved sustained freedom from pain without experiencing adverse events. Sustained freedom from pain was defined as pain free at 2 hours after taking medication with no recurrence of moderate or severe headache and no rescue medication 2 to 24 hours postdose. For the base-case analysis, efficacy and tolerability were assumed to be independent, so that SNAE was equal to the sustained pain-free rate multiplied by 1 minus the adverse event rate.
Direct costs
The direct costs comprised medical costs only. These included costs associated with health service resource use (physician visits, emergency room attendance, and hospitalisation) and medication costs (almotriptan or sumatriptan). The costs and the quantities were not analysed separately in terms of health service resource use. The health service costs were derived from a study published in 1999 that reported the economic burden of migraine in the USA. For the base-case analysis it was assumed that annual migraine-related costs were apportioned uniformly across attacks; the estimated cost per attack was obtained by dividing the annual health service cost per patient with migraine by the annual attack frequency. Therefore, in the base-case analysis, the total health service costs were assumed to be uninfluenced by the choice of triptan.
The drug costs were derived from a national source that provided prices approximating actual managed care pharmacy prices rather than average wholesale prices. It was assumed that every acute migraine attack was treated with one tablet of either almotriptan or sumatriptan. The costs were adjusted to 2004 prices using an annual inflation rate of 3%. Discounting was not necessary as the costs were estimated per episode of attack.
Statistical analysis of costs
The costs were treated deterministically. No statistical analysis of the costs was undertaken.
Indirect Costs
The indirect costs were not included in the analysis.
Currency

US dollars ($).
Sensitivity analysis
A sensitivity analysis was undertaken to test the robustness of the results under different sets of assumptions. The different scenarios examined in one-way sensitivity analyses involved: a relationship between efficacy and tolerability; various odds ratios (ORs) describing this relationship, varying from 0.1 (strongly negative relationship) to 10 (strongly positive relationship); and the assignment of costs only to patients not achieving sustained freedom from pain.
In addition, threshold analyses examined the number of tablets per attack required so that the agents under evaluation became equivalently cost-effective. This scenario was explored separately for positive, negative and independent relationships between efficacy and tolerability. Finally, a probabilistic analysis was carried out to assess the probability of almotriptan being the cost-effective option. This analysis utilised a range of values for SNAE, determined by the mean values and CIs for efficacy and adverse event rates for triptans that were taken from the published meta-analysis. Separate analyses were undertaken for different values of OR for the relationship between efficacy and tolerability.
Validity of estimate of measure of benefit
The estimation of benefits was based on the use of a composite measure, which incorporated both efficacy (expressed as sustained pain-free rate) and tolerability (expressed as rate free of adverse events) associated with the agents under assessment. The measure of efficacy used had been described as the ideal measure for assessing response to acute migraine therapy; freedom of adverse events had been stated to be an important outcome to patients. Hence, the measure of benefits used was appropriate for the analysis.
Validity of estimate of costs
All the categories of cost relevant to the perspective adopted (US health care payer) were included in the analysis. The costs and the quantities were not reported separately, which hinders the reproducibility of the results. The total annual costs associated with migraine attacks, which were derived from a published study, were evenly apportioned to each migraine attack regardless of the choice of triptan. Therefore, differences in efficacy and adverse event rates between triptans were not considered in the estimation of costs. However, this assumption favoured sumatriptan (because it has a lower efficacy rate and a higher adverse event rate than almotriptan), which proved to be the least cost-effective option. A sensitivity analysis was conducted to test the scenario of apportioning costs only between patients who did not achieve sustained freedom from pain. The drug unit costs used approximated actual managed care pharmacy prices rather than average wholesale prices. Discounting was not necessary, as the costs were estimated per migraine attack, and was not applied. The price year was stated, which increases the generalisability of the results.
